Recruiting
- Dec 6, 2018

NCT03582033: Phase 1 - A Safety Study of SEA-BCMA in Patients With Multiple Myeloma

Updated: Jul 15, 2022

NCT03582033: Phaae 1 - A Safety Study of SEA-BCMA in Patients With Multiple Myeloma

This trial will study SEA-BCMA to find out whether it is an effective treatment for multiple myeloma (MM) and what side effects (unwanted effects) may occur.

The study will have several parts. In Parts A and B, participants get SEA-BCMA by itself. This part of the study will find out how much SEA-BCMA should be given for treatment and how often. It will also find out how safe the treatment is and how well it works.

In Part C of the study, participants will get SEA-BCMA and dexamethasone. In Parts D and E, participants will get SEA-BCMA, dexamethasone, and either pomalidomide or nirogacestat. Dexamethasone and pomalidomide are both drugs that can be used to treat multiple myeloma. Nirogacestat is an experimental drug that can be used with SEA-BCMA to treat multiple myeloma. These parts of the study will find out whether these drugs are safe when used together.

Sponsor:

Seagen Inc.

ClinicalTrials.gov Identifier: NCT03582033

Official Title: A Phase 1 Study of SEA-BCMA in Patients With Relapsed or Refractory Multiple Myeloma

First Posted : July 10, 2018

Click here to see details on ClinicalTrials.gov

SGNBCMA-001

SEA-BCMA

SEA-BCMA is a Novel Empowered Antibody Targeting BCMA for Multiple Myeloma

Click here for details

Nirogacestat - gamma secretase inhibitor PF-03084014

View this agent in the NCI Thesaurus